In the Southern United States, there is a disproportionately high rate of HIV diagnoses amongst Black and Latino men who have sex with men. However, these groups are also less likely than their white counterparts to take PrEP, or pre-exposure prophylaxis, which can safely decrease a person’s likelihood of getting HIV through sex by about 99% when taken as prescribed.
Tagged: HIV
-
-
To help reach the UNAIDS 95-95-95 targets by 2025, the public health community must ensure that people living with HIV have access to antiretroviral therapy (ART). Access to this lifesaving medication is one issue; staying on it is another, because continuing ART is not always possible due to a variety of circumstances. In a project FHI 360 recently concluded in Nigeria, we demonstrated how machine learning can complement the efforts of health care workers to help people stay on ART.
-
Twenty years ago, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) was established to lead the global response to the HIV epidemic. Today, PEPFAR is a public health engine: a critical platform for strengthening health systems, preparing for and responding to pandemics, and enabling global health security. Here, we share how PEPFAR made it possible for FHI 360’s teams to effectively respond to COVID-19 in countries with established HIV infrastructure.
-
Over the past decade, there have been remarkable advances in the HIV prevention, treatment and epidemic control tools used by the global community working to address HIV. Investments in scientific discovery and implementation research have furthered our understanding of the factors driving the epidemic, as well as the biology of viral transmission. Prevention, diagnostic and treatment strategies have improved immensely, as have antiretroviral drugs.
-
While COVID-19 has been at the center of health concerns since early 2020, the fight to end HIV continues. How are HIV communicators in the United States effectively engaging with their priority audiences? Here, four HIV communicators explain why they are passionate about their work and discuss how, in the current environment, they can best reach people in the United States who historically have had to bear the largest burden of HIV.
-
Shaping the world we want to live in
An Interview with
Dr. Timothy Mastro, Chief Science Officer, FHI 360
As FHI 360 marks its 50th anniversary, explore our history of solutions and future of possibilities.
Dr. Timothy Mastro, FHI 360’s Chief Science Officer, offers his perspective on where we’ve been, where we’re going and what’s at stake in human development.
-
The Cookie Jar is a Facebook group run by FHI 360’s Accelerating Progress in Communities (APC 2.0) project to support young women in Botswana in shifting social and gender norms. Members talk about issues like HIV risks, gaps in knowledge about infections and access to treatment. Typically, young women like me do not use HIV services despite risks of infection or violence in relationships. In Botswana, many young women engage in intergenerational and transactional sex. The Cookie Jar provides a place for young women to seek information, find out how to get care and receive peer support.
-
As Black American public health professionals, we know that one pervasive question for Black Americans today is, “So, are you getting the COVID vaccine?”
-
Digital communications and media are now part of everyday life for many people around the world. But while people have turned to smartphones for entertainment, socializing and commerce, the health community is still working to make services, outreach and treatment digitally accessible. Examining successful applications allows us to understand what approaches might be possible for digital health services. During the COVID-19 pandemic, it is more crucial than ever that digital health resources provide support for people to access from their homes.
-
While much progress has been made to end the HIV epidemic, not enough has been done to put the power of prevention directly in women’s hands. The dapivirine ring, a flexible silicone ring inserted monthly into the vagina, can change this. If approved by regulators, the ring would be the first discreet, long-acting HIV prevention tool available specifically for women. The ring would complement daily oral HIV pre-exposure prophylaxis (PrEP) as another biomedical tool in the fight against HIV.
Recent evidence suggests significant acceptability of and demand for vaginal rings as a drug-delivery platform among women who used the dapivirine ring during clinical trials — and also among policymakers and other stakeholders in countries with a high HIV burden. To better understand these perspectives, the OPTIONS Consortium interviewed policymakers, implementers and civil society leaders in seven sub-Saharan African countries about possibilities for introduction and scale-up of the dapivirine ring. An analysis of the interviews shows widespread enthusiasm for the ring as part of comprehensive HIV prevention programming.